Despite the pervasive economic effects of mental health challenges, major players in the pharmaceutical industry have failed to keep up with both the scale of the crisis and recent advances in the literature that may offer a sustainable solution. While research has identified the clinical potential of psychoactive and psychedelic treatments for a variety of mental health conditions, conservative pharmaceutical companies have largely shied away from the regulatory demands of investigating such compounds.
Mind Cure specializes in the development, manufacturing, and distribution of nootropics that will soon be available online and in retail stores under the company’s Mind Cure brand. Mind Cure is positioned to capitalize on growing awareness among consumers regarding Reishi, Lion’s Mane, and Turkey Tail mushrooms, all of which have been recognized to deliver an impressive range of health benefits including reduced stress, a bolstered immune system, and increased vitality.
Mind Cure’s Company Highlights
- Over three million Canadians and 10 million Americans suffer from anxiety disorders
- By 2026, the estimated cost of the global anxiety disorders and depression treatment market is $18.9 billion
- Research has identified the clinical potential for psychoactive and psychedelic treatments to combat a variety of mental health conditions.
- Mind Cure’s “Five Spheres” approach is a strategic path towards finding and delivering multipliers of value to shareholders
- Mind Cure is working towards a cloud-based digital therapeutics platform for treating mental health
- Mind Cure has developed a psychedelic dream team with expertise and experience in neuroscience and psychedelics
- Mind Cure is positioned to capitalize on growing awareness among consumers regarding Reishi, Lion’s Mane, and Turkey Tail mushrooms
- Mind Cure’s MoonBeam brand is expected to soon be available online and in retail stores
Get access to more exclusive Psychedelics Stock profiles
here.
Keep reading...Show less
View original content: https://www.newswire.ca/en/releases/archive/January2021/21/c6395.html 